Leaflet TANDEMACT 30mg / 4mg tablets


Indicated for: type 2 diabetes mellitus

Substance: pioglitazone + glimepiride (thiazolidinedione antidiabetic + sulfonylurea antidiabetic)

ATC: A10BD06 (Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Combinations of oral blood glucose lowering drugs)

The combination of pioglitazone and glimepiride is used for the treatment of type 2 diabetes, helping to control blood glucose levels. Pioglitazone increases the sensitivity of cells to insulin, while glimepiride stimulates insulin secretion from the pancreas.

The medication is taken orally, usually once daily, and should be used as directed by your doctor. It is important to combine the treatment with a healthy diet and regular exercise to achieve the best results.

Side effects may include hypoglycemia, weight gain, fluid retention, or, in rare cases, heart failure or allergic reactions.

Patients should inform their doctor about any other medications being used or pre-existing conditions, such as heart or liver diseases, to ensure the safe use of this combination.

General data about TANDEMACT 30mg / 4mg

  • Substance: pioglitazone + glimepiride
  • Date of last drug list: 01-07-2013
  • Commercial code: W51752002
  • Concentration: 30mg / 4mg
  • Pharmaceutical form: tablets
  • Quantity: 28
  • Product type: original
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Concentrations available for pioglitazone + glimepiride

  • 30mg/2mg
  • 30mg/4mg
  • 45mg/4mg